Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma

Authors:

Abstract
The development of antiangiogenic agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, sorafenib, bevacizumab and temsirolimus) has revolutionized the treatment of metastatic renal clear-cell carcinoma. Adverse events attributed to these agents targeting the vascularization include cardiovascular effects. We report here a case of aortic dissection in a patient treated by sunitinib and discuss the cardiovascular toxicity of sunitinib.